Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
197975
Reference Type
Journal Article
Subtype
Review
Title
Pharmacokinetics of PCBs
Author(s)
Matthews, HB; Dedrick, RL
Year
1984
Is Peer Reviewed?
Yes
Journal
Annual Review of Pharmacology and Toxicology
ISSN:
0362-1642
EISSN:
1545-4304
Report Number
NIOSH/00168261
Volume
24
Issue
ED.
Page Numbers
85-103
Language
English
PMID
6428301
DOI
10.1146/annurev.pa.24.040184.000505
Web of Science Id
WOS:A1984SM26700006
Abstract
The pharmacokinetics of PCBs are complicated by numerous factors, not the least of which is the existence of up to 209 different chlorinated biphenyls. Whereas all PCB congeners are highly lipophilic and most are readily absorbed and rapidly distributed to all tissues, PCBs are cleared from tissues at very different rates, and the same congeners may be cleared at different rates by different species. With the exception of special situations in which PCBs may be passively eliminated in lipid sinks, e.g. milk or eggs, clearance is minimal prior to metabolism to more polar compounds. Rates of PBC metabolism vary greatly with species and with the degree and positions of chlorination. Mammals metabolize these compounds most rapidly, but even among mammalian species rates of metabolism vary greatly. In all species studied, the more readily metabolized chlorinated biphenyls have adjacent unsubstituted carbon atoms in the 3-4 positions. Congeners that do not have adjacent unsubstituted carbon atoms may be metabolized very slowly and are therefore cleared very slowly. These PCBs not readily cleared concentrate in adipose tissue. A physiologic pharmacokinetic model best illustrates how the concentrations of PCBs in all tissues approach equilibrium with the blood and with one another. Thus, the model illustrates how a depot of PCBs in any tissue, e.g. adipose tissue, will result in exposure of all tissues in proportion to the respective tissue/blood ratios and the body burden. The disposition of a number of PCBs in the rate has been accurately described by a physiologic model, and the model has been extrapolated to predict the disposition of these same PCBs in the mouse (58). Therefore, the physiologic pharmacokinetic model is believed to offer the best opportunity to extrapolate data obtained with laboratory animals to predict the disposition of PCBs in other species, including man. Most of the parameters of a model of PCB disposition in man are available or could be estimated. The major limitation to the construction of such a model is the absence of accurate estimates of metabolic clearance of individual PCBs by man. Accurate estimates of metabolic clearance depend on development of suitable in vitro methods to accurately predict clearance in vivo.
Keywords
Animals; Biotransformation; Eggs/analysis; Feces/analysis; Humans; Kinetics; Milk/metabolism; Models, Biological; Polychlorinated Biphenyls/metabolism/urine; Species Specificity; Tissue Distribution; 0 (Polychlorinated Biphenyls)
Tags
IRIS
•
PCBs
Litsearches
PubMed
WoS
ToxLine
Initial Filter
Reviews
Remaining
LitSearch August 2015
Pubmed
Toxline
WoS
Cited (Nov 2012)
Targeted review search
Source
NAAQS
•
ISA-PM (2019)
In Scope
Exposure
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity